Overview

Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx)

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

This study is an open-label, single arm,phase II trial with a safety run in designed to determine the efficacy and safety of pembrolizumab + CapeOx. as first line therapy in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Capecitabine
Oxaliplatin
Pembrolizumab